U.S. tariffs impact<\/a> by increasing the volume of manufacturing stateside. For the last remaining drug, the company has started tech transfer weeks ago to enable its production in the U.S. for the first time, according to Schinecker.<\/p>\n\u201cWe are operating in the U.S. at 50% drug substance capacity,\u201d Schinecker said. \u201cThis gives us plenty of room to scale our manufacturing in the U.S.\u201d<\/p>\n
Because Roche has kept its intellectual property in the U.S. rather than shifting to more tax-friendly countries like Ireland, \u201cI believe we\u2019re well-positioned compared to other companies,\u201d the Roche chief said.<\/p>\n
President Donald Trump has targeted Ireland in his pharmaceuticals tariff threats, having floated import tax levels as high as 200% for drugs from the European country, although it\u2019s not entirely clear if those levies will affect IP.<\/p>\n
In the near term, Roche has bulked up its inventories in China and the U.S. for the next few weeks, according to Schinecker.<\/p>\n
\u201cThings can change quite quickly,\u201d the CEO said. \u201cBut for us as a company, it\u2019s always important that [\u2026] we are prepared for all scenarios.\u201d<\/p>\n
Schinecker stressed that the new U.S. investments are necessary and that they won\u2019t lead to increases in Roche\u2019s overall capital expenditures. The company has been operating at about 3.5 billion Swiss francs to 4 billion Swiss francs in capital expenditures each year, he noted.<\/p>\n
\u201cThese are new investments in terms of new areas in technology such as continuous glucose monitoring, but also in new manufacturing modalities where we need to invest in because of our research work in incretin and amylin, which are both peptides,\u201d he said.<\/p>\n
In a $1.65 billion upfront deal with Zealand Pharma signed in March, Roche gained the right to codevelop and co-commercialize long-acting amylin analog petrelintide in the weight-loss field.<\/p>\n
Investment in the U.S. doesn\u2019t mean Roche has stopped growing its presence in other countries, Schinecker said, pointing to the company\u2019s ongoing manufacturing expansion projects in China, Switzerland and Germany.<\/p>\n
\u201cOver the past years, it\u2019s really been our strategy to make sure that we have strong manufacturing presence in all of the major markets,\u201d Schinecker said.<\/p>\n
In the first quarter of 2025, Roche recorded 11.95 billion Swiss francs in sales, up 9% year over year. These include 6.22 billion Swiss francs from the U.S., which enjoyed a foreign exchange windfall from a depreciating U.S. dollar.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S.…\n","protected":false},"author":2,"featured_media":115927,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[351,18,4175,230,41939,625,228,2536,44395,134,112,5074],"class_list":["post-115926","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-china","tag-donald-trump","tag-drug-manufacturing","tag-earnings","tag-fierce-pharma-homepage","tag-financials","tag-manufacturing","tag-pharma","tag-pharma-ceo","tag-roche","tag-tariffs","tag-thomas-schinecker"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117101467067517306","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/115926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=115926"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/115926\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/115927"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=115926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=115926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=115926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}